TNF Inhibitor-Induced Psoriasis
TNF blocker Induced Psoriasis: Take Home Messages
TNF blocker Induced Psoriasis: Take Home Messages
A study of 194 knee OA patients received either 1200 mg chondroitin sulfate or celecoxib 200 mg daily, and clinical and MRI outcomes were assessed at 1 and 2 years.
ACR 2015 RA treatment guidelines were published yesterday, nearly a year after they were preliminarily presented at the 2014 ACR meeting in Boston. After a year of review and revision these have been posted.
In September, the FDA issued warnings that the dipeptidyl peptidase-4 (DPP4) inihibitor Invokana may cause a dose-dependant increased risk of bone fractures. This was based on a review of nin
An FDA Advisory Panel reviewed the safety of fluoroquinolones and their use to treat sinus infections, urinary-tract infections and bronchitis.
As risk of hip fracture increases with advanced age, our knowledge of risk factors for hip fracture among very old people remains limited.
"Doc....the pain is killing me."
This oft heard patient complaint may be truer than you think.
Certain serologic and clinical features can help predict a chronic disease course among children with juvenile idiopathic inflammatory myopathies (JIIM), a large registry study showed.
Biosimilars are in the news and will be prominently on parade at next week's ACR meeting in San Francisco. Biosimilars are similar to, but not the same as, innovator biologics.
JAMA reports the results of trends in drug use in the USA over a 13 year period using data derived 37959 adults survey in the National Health and Nutrition Examination Survey (NHANES).
A retrospective population-based study from New Zealand examined the epidemiology, clinical features, and microbiology of adult native joint septic arthritis.
To assess the prevalence and magnitude of healthcare costs associated with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in the USA, researchers analyzed adminstrative data from Truven Health MarketScan Commercial and Medicare Supplemental databases.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.